Fibrodysplasia Ossificans Progressiva Treatment Market it would grow upto USD 684.28 million by 2030

Published October 25, 2023

Fibrodysplasia Ossificans Progressiva Treatment MarketFibrodysplasia Ossificans Progressiva Treatment Market study by “Data Bridge Market Research” provides details about the market dynamics affecting the Healthcare Business Intelligence market, Market scope, Market segmentation, and overlays shadow upon the leading market players highlighting the favourable competitive landscape and trends prevailing over the years.

Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary disorder. The market is expected to expand rapidly in the few years. Introduction of novel therapies and rise in cases of fibrodysplasia ossificans progressiva are likely to be major drivers of the market. Increase in demand for the treatment of this disease and increase in awareness associated with FOP are also projected to drive the market during the forecast period.

Data Bridge Market Research analyses a growth rate in the fibrodysplasia ossificans progressiva treatment market in the forecast period 2023-2030. The expected CAGR of fibrodysplasia ossificans progressiva treatment market tend to be around 4% in the mentioned forecast period. The market was valued at USD 500 million in 2022 and it would grow upto USD 684.28 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Request a Sample PDF:

Fibrodysplasia ossificans progressiva (FOP) is a type of rare genetic disorder wherein the muscle tissue and connective tissue, such as the tendons and ligaments are substituted by bone, forming bone outside the skeleton that limits the movement of that specific part of the body. This can cause malformations such as shortened great toe with a malformed distal first metatarsal, abnormally short fingers and toes, inward turning of the great toe toward the other toes, or permanent fixation of the fifth finger in a bent position.


  • Growing Incidence of Fibrodysplasia ossificans progressiva treatment

As per the Journal of Rare Disease Research and Treatment, in 2016, the incidence of FOP ranged considerably from around 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia Pacific.  Therefore, it acts as a major driver in the market growth.

  • Increase in the number of R&D activities       

The market’s growth is fuelled by the increase in the number of R&D activities. This will provide much beneficial opportunities for the market. For instance, in January 2020, Regeneron Pharmaceuticals, Inc., which is an American pharmaceutical company, showcased the results from a Phase 2, double-blind placebo-controlled trial, LUMINA-1, the trial was originated to assess garetosmab for the treatment of fibrodysplasia ossificans progressiva.


  • Increased Partnerships and Collaborations

There have been increased partnerships and collaborations between market players that lead to the growth of the market.  For instance, In October 2019, Clementia Pharmaceuticals, a subsidiary of Ipsen, and Blueprint Medicines Corporation came into an exclusive license agreement to commercialize and develop BLU-782, which is a highly selective investigational ALK2 inhibitor, that is indicated for the treatment of fibrodysplasia ossificans progressiva (FOP).

Explore the Full Report:

Key players operating in the fibrodysplasia ossificans progressiva treatment market include:

  • Pfizer Inc. (U.S.)
  • Abbvie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Merck & Co Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • AstraZeneca (U.K.)
  • Lilly (U.S.)
  • Zydus Group (India)
  • Fresenius Kabi AG (Germany)
  • Accord Healthcare, Inc. (U.S.)
  • Regeneron Pharmaceuticals Inc (U.S.)
  • Blueprint Medicines Corporation (U.S.)
  • Ipsen Pharma (France)
  • NATCO Pharma Limited (India)
  • Thermo Fisher Scientific (U.S.)
  • bioMérieux S.A. (France)
  • Bayer AG (Germany)
  • Bristol Myers Squibb Company (U.S.)
  • Abbott (U.S.)

Fibrodysplasia Ossificans Progressiva Treatment Market Scope

The fibrodysplasia ossificans progressiva treatment market is segmented on the basis of drug class, drug, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Corticosteroids
  • NSAIDs
  • Bisphosphonates
  • Others



  • Medication
  • Occupational Therapy
  • Surgery

Route of Administration

  • Oral
  • Topical
  • Parenteral


  • Hospitals
  • Research Institutes
  • Specialty Clinics

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others

Investing in this study will provide you with access to valuable information, which includes:

  1. Thorough industry coverage on a global scale, with detailed breakdowns by region.
  2. In-depth analysis of regional markets, encompassing North America, Europe, Asia Pacific, South America, and the Middle East & Africa.
  3. Country-specific market size breakdowns for key countries with significant market shares.
  4. Comprehensive data on market share and revenue/sales from leading industry players.
  5. Examination of market trends, such as emerging technologies, products, and startups, along with PESTEL Analysis, SWOT Analysis, Porter’s Five Forces, and more.
  6. Detailed market size data, including segmentations by application and industry verticals.
  7. Projections and forecasts for the future growth and development of the market.

This Market Intelligence Report Analyses Some of the Most Crucial Concerns:

  1. Anticipated developments in the major segments of the international market in the coming years.
  2. Identification of key players poised to dominate the market in the future.
  3. Assessment of the leading suppliers and producers in this industry.
  4. Examination of growth and expansion strategies implemented by successful industry players.
  5. Insight into sectors expected to experience the most significant demand growth in the near future.
  6. Analysis of the various buyer segments within this market.
  7. Prediction of the regional powerhouse likely to emerge as the dominant player in the international market.
  8. Exploration of the potential impact of a new coronavirus pandemic.
  9. Evaluation of challenges faced by established market players due to the entry of newcomers and strategies to overcome them.

Browse the Comprehensive Research Report Summary with Table of Contents:

Top DBMR Healthcare Reports:        

Global Bipolar Disorder Treatment Market – Industry Trends and Forecast to 2029

Global Diabetic Macular Edema Treatment Market – Industry Trends and Forecast to 2029

Global 3D Cone Beam Computed Tomography (CBCT) Systems Market – Industry Trends and Forecast to 2029

Global Pregnancy Care Products Market – Industry Trends and Forecast to 2029

Global Hair and Care Market – Industry Trends and Forecast to 2030

Global Vascular Stent Market – Industry Trends and Forecast to 2029

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:-

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475


CDN Newswire